SQUAREMIND develops an integrated dermatology platform combining robotics, high-resolution imaging and artificial intelligence to digitize and map the entire skin surface in minutes. Its flagship product, Swan™, automates image acquisition at dermoscopic resolution and pairs that capture with AI-assisted review and longitudinal lesion tracking. The company positions the technology to increase clinicians’ diagnostic throughput and to standardize documentation for follow-up and screening. SquareMind plans to industrialize production and expand commercial teams to deploy the platform across Europe and the United States. The startup raised $18 million in the current financing (including a prior pre-Series A) to fund these plans. It is led by cofounder and CEO Ali Khachlouf and was founded in Paris.

Total raised

$18M

Funding rounds

1

Latest round

Series A

Latest activity

Apr 2026